open access

Vol 44, No 3 (2010)
ARTYKUŁ ORYGINALNY
Submitted: 2009-03-15
Get Citation

The –A162G polymorphism of the PON1 gene and the risk of sporadic amyotrophic lateral sclerosis

Dorota Zawiślak, Monika Ostrowska, Aleksandra Golenia, Monika Marona, Barbara Tomik, Paweł Wołkow, Elżbieta Gryz-Kurek, Andrzej Szczudlik, Agnieszka Słowik
DOI: 10.1016/S0028-3843(14)60038-4
·
Neurol Neurochir Pol 2010;44(3):246-250.

open access

Vol 44, No 3 (2010)
ARTYKUŁ ORYGINALNY
Submitted: 2009-03-15

Abstract

Background and purpose

Sporadic amyotrophic lateral sclerosis (sALS) is a devastating neurodegenerative disease, which results from complex genetic and environmental interactions. Recent studies have reported an association between several polymorphisms of the PON1 and PON2 genes and risk of sALS. The aim of the present study was to identify an association between the – A162G polymorphism of the promoter region of the human PON1 gene and the risk of sALS in a Polish population.

Material and methods

We included 259 patients with a diagnosis of definite or probable sALS (76 bulbar onset, 183 limb onset) and 694 healthy controls matched for age and sex. The diagnosis of ALS was established according to El Escorial criteria. The polymorphism was studied by Single Nucleotide Polymorphism Real-Time Polymerase Chain Reaction analysis.

Results

No overall difference in the PONI – A162G genotype and allele distribution was seen between cases and controls (all p > 0.05). There was, however, a difference in the A allele frequency when the bulbar onset group was compared to the controls (p = 0.03), but this significance disappeared after the Bonferroni correction.

Conclusions

The results did not show that the – A162G polymorphism of the PON1 gene is a risk factor of sALS in a Polish population; it may affect, however, bulbar onset of the disease.

Abstract

Background and purpose

Sporadic amyotrophic lateral sclerosis (sALS) is a devastating neurodegenerative disease, which results from complex genetic and environmental interactions. Recent studies have reported an association between several polymorphisms of the PON1 and PON2 genes and risk of sALS. The aim of the present study was to identify an association between the – A162G polymorphism of the promoter region of the human PON1 gene and the risk of sALS in a Polish population.

Material and methods

We included 259 patients with a diagnosis of definite or probable sALS (76 bulbar onset, 183 limb onset) and 694 healthy controls matched for age and sex. The diagnosis of ALS was established according to El Escorial criteria. The polymorphism was studied by Single Nucleotide Polymorphism Real-Time Polymerase Chain Reaction analysis.

Results

No overall difference in the PONI – A162G genotype and allele distribution was seen between cases and controls (all p > 0.05). There was, however, a difference in the A allele frequency when the bulbar onset group was compared to the controls (p = 0.03), but this significance disappeared after the Bonferroni correction.

Conclusions

The results did not show that the – A162G polymorphism of the PON1 gene is a risk factor of sALS in a Polish population; it may affect, however, bulbar onset of the disease.

Get Citation

Keywords

amyotrophic lateral sclerosis, PON1, polymorphism

About this article
Title

The –A162G polymorphism of the PON1 gene and the risk of sporadic amyotrophic lateral sclerosis

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 44, No 3 (2010)

Pages

246-250

DOI

10.1016/S0028-3843(14)60038-4

Bibliographic record

Neurol Neurochir Pol 2010;44(3):246-250.

Keywords

amyotrophic lateral sclerosis
PON1
polymorphism

Authors

Dorota Zawiślak
Monika Ostrowska
Aleksandra Golenia
Monika Marona
Barbara Tomik
Paweł Wołkow
Elżbieta Gryz-Kurek
Andrzej Szczudlik
Agnieszka Słowik

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl